Press coverage about NuVasive (NASDAQ:NUVA) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NuVasive earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned news headlines about the medical device company an impact score of 47.5741114598314 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

A number of equities research analysts recently weighed in on the stock. BMO Capital Markets cut their price objective on shares of NuVasive from $85.00 to $69.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 25th. BTIG Research set a $74.00 price objective on shares of NuVasive and gave the company a “buy” rating in a research note on Wednesday, October 25th. Needham & Company LLC reiterated a “sell” rating on shares of NuVasive in a research report on Wednesday, October 25th. Wells Fargo & Company reiterated an “outperform” rating and issued a $65.00 price target (down from $81.00) on shares of NuVasive in a research report on Wednesday, October 25th. Finally, J P Morgan Chase & Co set a $78.00 price target on shares of NuVasive and gave the stock a “buy” rating in a research report on Wednesday, October 25th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. NuVasive has an average rating of “Buy” and an average price target of $72.67.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings results on Tuesday, October 24th. The medical device company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.04. NuVasive had a return on equity of 13.65% and a net margin of 6.36%. The business had revenue of $247.40 million for the quarter, compared to analyst estimates of $255.70 million. During the same quarter in the prior year, the firm posted $0.40 earnings per share. The firm’s revenue for the quarter was up 3.3% compared to the same quarter last year.

NuVasive declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, October 24th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the medical device company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

In other news, CEO Gregory T. Lucier purchased 5,000 shares of the business’s stock in a transaction dated Thursday, August 17th. The shares were acquired at an average price of $66.22 per share, with a total value of $331,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Gregory T. Lucier purchased 2,000 shares of the business’s stock in a transaction dated Tuesday, August 29th. The shares were purchased at an average cost of $61.52 per share, for a total transaction of $123,040.00. The disclosure for this purchase can be found here. Corporate insiders own 1.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Insider Buying and Selling by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.